[A25-23] Pembrolizumab (urothelial cancer, first line treatment, combination with enfortumab vedotin) – Addendum to Project A24-99
Last updated 03.04.2025
Project no.:
A25-23
Commission:
Commission awarded on 11.02.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
First-line treatment of adult patients with unresectable or metastatic urothelial carcinoma
Result of dossier assessment:
unchanged after addendum:
- Patients for whom cisplatin-based therapy is a suitable treatment option: hint of non-quantifiable added benefit
- Patients for whom cisplatin-based therapy is not a suitable treatment option: hint of major added benefit
- Patients for whom cisplatin-based and carboplatin-based therapy is not a suitable treatment option: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
DOI:
https://doi.org/10.60584/A25-23
| Project no. | Title | Status |
|---|---|---|
| A24-99 | Pembrolizumab (urothelial cancer, first line) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2025-04-03 A G-BA decision was published.